AGY THERAPEUTICS SELECTED TO PRESENT AT FUTURE LEADERS IN BIOTECH INDUSTRY CONFERENCE
SOUTH SAN FRANCISCO, Calif. April 2, 2003 AGY Therapeutics Inc. today announced that Karoly Nikolich, Ph.D., the company's founder and chief executive officer, will present at the Future Leaders in the Biotech Industry Conference. His presentation will be held on Thursday, April 3 at 10:40 to 11:05 a.m. EST in room 302/303 at the Millennium Broadway Hotel and Conference Center in New York.
Dr. Nikolich will provide an update on AGY Therapeutics' proprietary technology platform for functional gene discovery and identification of pathways underlying central nervous system (CNS) diseases, as well as the development of pre-clinical candidates for the treatment of stroke and cognitive disorders. In addition, Dr. Nikolich will discuss the company's neuro-oncology program, which already has identified highly specific targets that could lead to treatments and new diagnostic tests for the most common and deadly types of brain tumors.
"AGY's innovative, methodical approach to CNS disease drug discovery is leading us to improved understanding of disease pathology and development of novel treatments," said Dr. Nikolich. "We are advancing our lead programs toward the clinic and continue to validate many potential drug targets for stroke, Alzheimer's disease and other diseases to add to our drug discovery efforts. We look forward to the opportunity to share these and other company developments with this important group." The Future Leaders in Biotech Conference is a forum for select companies "best positioned to provide market leadership" to present to top financial professionals, including institutional investors, investment bankers and sellside analysts. The annual conference is sponsored by BioCentury Publications and Thomson Financial/Carson.
For additional information contact:
Karoly Nikolich, Ph.D.
Chief Executive Officer
AGY Therapeutics, Inc.
AGY Therapeutics' proprietary imAGYne platform defines the intra- and extra-cellular signaling pathways that underlie the pathological progression of central nervous system (CNS) diseases, so novel, high-quality targets can be carefully selected and functionally validated with the most valuable targets advanced into drug discovery and development. To date, AGY Therapeutics has identified and characterized a vast number of promising drug targets to treat or diagnose CNS diseases.
About AGY Therapeutics
AGY Therapeutics, Inc., a privately-held biotechnology company, is dedicated to discovering and developing novel treatments for central nervous system (CNS) diseases, including stroke, Alzheimer's disease, depression, brain tumors and obesity.
This news release contains forward-looking statements about future research and development efforts. These statements represent our judgment as of the date of this news release and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. In particular, we face risks and uncertainties that further research into these genes may not go forward as planned or that future scientific data on these genes may not provide supportive data for the diseases we are targeting.